Keyphrases
Response to Treatment
100%
Durable Response
100%
Brentuximab Vedotin
100%
Desmoplastic Small Round Cell Tumor (DSRCT)
100%
Nectin-4
50%
Chemotherapy
25%
Older Adults
25%
Tumor
25%
Next-generation Sequencing
25%
Disease Control
25%
Poor Prognosis
25%
Poor Differentiation
25%
Standard of Care
25%
Clinical Benefit
25%
Aggressive Tumor
25%
Young Males
25%
Pembrolizumab
25%
Potential Therapeutic Strategies
25%
Gene Rearrangement
25%
Bladder Wall
25%
Urothelial Carcinoma
25%
Multiple Lines
25%
Pathognomonic
25%
Partial Response
25%
Antibody-drug Conjugate
25%
Hematuria
25%
Rare Tumors
25%
Fusion Gene
25%
Challenging Diagnosis
25%
IHC Staining
25%
Rare Sarcoma
25%
Medicine and Dentistry
Desmoplastic Small Round Cell Tumor
100%
Enfortumab Vedotin
100%
Neoplasm
50%
Diseases
50%
Nectin
50%
Case Presentation
25%
Transitional Cell Carcinoma
25%
Antibody-Drug Conjugate
25%
Next Generation Sequencing
25%
Pathognomonic
25%
Bladder Wall
25%
Gene Rearrangement
25%
Fusion Gene
25%
Pembrolizumab
25%
Hematuria
25%
Connective Tissue Cancer
25%